Avita Medical Ltd. (ASX: AVH), the regenerative medicine company,has announced the hiring of Dr. Michael Mendicino as R&D Programme Manager, Regenerative Medicine. Dr. Mendicino will be based in the U.S. California office.

Dr. Mendicino will have primary responsibility for the design and conduct of the company’s applied research programme in regenerative medicine and tissue engineering. Dr. Mendicino will oversee R&D efforts related to Avita’s current regenerative medicine products as well as expansion of the company’s product lines.

Dr. Mendicino holds a Ph.D. in Transplant Immunology from the University of Toronto, Toronto, Canada, where he also successfully completed a Strategic Training Programme in Regenerative Medicine. He did his undergraduate studies in Molecular Genetics and Biology. He has held scientific management positions in industry and research organisations, including Senior Research Associate at Revivicor Inc., and most recently, Biology and Immunology Investigator at the National Center for Regenerative Medicine and Scientist at Athersys Inc. (Nasdaq:ATHX) in Cleveland, Ohio, where he was responsible for a research project developing the clinical transplant of adult stem cells.

Avita Medical CEO Dr. William Dolphin said: “Michael brings extensive experience and key skills critical to the company’s plans for expansion of product lines and clinical indications in the field of regenerative medicine. I am delighted to have Dr. Mendicino join us at Avita. We will all benefit greatly from his expertise and talent.”

ABOUT RECELL® SPRAY-ON SKIN™

The company’s lead product, ReCell^® Spray-On Skin, has been designed for use in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell allows in-theater preparation of a spray-on suspension consisting of cells derived from a small (2x2cm), thin (0.15-0.20mm) biopsy of a patient’s own skin that is sufficient to cover an area up to 80 times the size of the biopsy. The ReCell suspension contains basal keratinocytes, melanocytes, fibroblasts and Langerhans cells. The metabolically responsive epithelial cells migrate across the wound surface, leading to regeneration of skin of normal color and texture. ReCell requires only a minimal donor site and is immediately available as a cell-based spray at the patient’s bedside.

ReCell^® is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell^® is not available for sale in the United States; in the U.S. ReCell^® is an investigational device limited by federal law to investigational use.

ABOUT AVITA MEDICAL LTD.

Avita Medical ASX:AVH () is a publicly listed medical technology company that develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Using patented and proprietary tissue culture, collection and application technology, the company is able to provide innovative treatment solutions derived from a patient’s own skin.

This news release may include forward-looking statements that involve risks and uncertainties. You can identify these statements by the use of words such as “anticipate”, “estimate”, “expect”, “project”, “potential”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. These forward-looking statements speak only as at the date of this release and are based on management’s expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of Avita Medical that could cause actual results to differ materially from such statements. Avita Medical makes no undertaking to subsequently update or revise the forward-looking statements made in this release to reflect events or circumstances after the date of this release. This document is intended to provide background information only and does not purport to make any recommendation upon which you may reasonably rely without taking further and more specific advice.